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Opinion statement
x Medical treatment in Wilson’s disease includes chelators (D-Penicillamine and
Trientine) or zinc salts that have to be maintain all the lifelong. This
pharmacological treatment is categorized into two phases; the first being a de-
coppering phase and the second a maintenance’s one. The best therapeutic
approach remains controversial, as only a few non-controlled trials have
compared these treatments. During the initial phase, progressive increase of
chelators’ doses adjusted to exchangeable copper and urinary copper might
help to avoid neurological deterioration. Liver transplantation is indicated in
acute fulminant liver failure and decompensated cirrhosis; in cases of
neurologic deterioration, it must be individually discussed. During the
maintenance phase, the most important challenge is to obtain a good
adherence to lifelong medical therapy.
x Neurodegenerative diseases that lead to a mislocalization of iron can be
caused by a culmination of localized overload (pro-oxidant siderosis) and
localized deficiency (metabolic distress). A new therapeutic concept with
conservative iron chelation rescues iron-overloaded neurons by scavenging
labile iron and, by delivering this chelated metal to endogenous apo-
transferrin, allows iron redistribution to avoid systemic loss of iron.
1. Introduction
Heavy metals, present in trace concentrations in the environment, are naturally
occurring elements with a relative high density compared to water [1]. Some of them
(e.g. lead, aluminium, mercury) are non-essential with high degree of toxicity for
humans. When absorbed or inhaled in high doses, they usually damage specific
organs such as kidneys, bone, brain and nerves (see Table 1) and may also be
implicated in the pathogenesis of neurodegenerative diseases, particularly
Alzheimer's or Parkinson’s disease.
Other bioavailable metals (e.g. copper, iron, zinc, manganese) are essential nutrients
for various biochemical and physiological human functions, and especially for brain
development and metabolism. When their concentrations are out of the normal
range, due to abnormal accumulation or inadequate supply from various origins (i.e.
genetic or toxicity), these microelements may play a role in disease pathogenesis,
especially through free radical formation.
This article will focus on the neurologic manifestations in connection with copper, iron
and manganese, three of these essential nutrients that are normally utilized in
biology systems due to their ease in transition of valence state.
Copper and Central Nervous System
1. Copper metabolism and brain pathology
During a normal diet, the daily intake of copper is about 2-3 mg. It is absorbed by the
enterocytes, stored with metallothioneins, copper-selective chaperone proteins and
then exported by Cu-ATPase ATP7A to the liver via the portal vein. In hepatocytes,
metallothioneins and ATPases (ATP7A and ATP7B) interact and allow the
hepatobiliary system to maintain a physiological copper homeostasis.
Despite the concentration of copper being higher in the liver, it is also predominantly
present in the normal brain. It has a heterogeneous distribution with stronger
concentration in the grey matter (e.g. basal ganglia, Substantia Nigra, dentate
nucleus, cortex) than in the white matter [2]. The current model for copper transport
through the brain is that the blood–brain barrier (BBB) regulates the influx of copper
into the brain and the blood–CSF barrier (BCB) contributes to the maintenance of the
copper homeostasis in the brain extracellular fluids [3]. This tight regulation mediated
by specific copper transporters and chaperones present at these two brain barriers,
allows the copper concentration in the CSF to be maintained at a 50-100 fold lower
level than in the serum [4].
Copper acts as a fundamental catalytic cofactor for numerous enzymes and proteins
involved in growth and brain development. Examples include the synthesis of
cytochrome C oxidase, superoxide dismutase 1, dopamine-beta-hydroxylase,
norepinephrine, and amyloid precursor protein as well as the functioning of
ceruloplasmin and others metalloproteins [5]. Deficiency in copper caused by an
inadequate supply can result in impaired energy production, increased oxidative
damage, tissue iron accumulation as well as aberrant neuropeptide synthesis and
processing. Increased CNS copper level is found in genetic disorders such as
Wilson’s disease (see section below), and in neurodegenerative diseases like
Alzheimer’s disease and amyotrophic lateral sclerosis where CNS copper is reported
to be two-fold higher than in age matched controls [6].
2. Disorders caused by a genetic mutation in a copper regulatory protein
Wilson’s disease (WD)
WD is an autosomal recessive disorder due to mutations in the ATP7B (Wilson
disease protein) gene that is predominantly expressed in the liver. Defective ATP7B
function impairs both copper incorporation to ceruloplasmin in hepatocytes and
copper release into the bile, resulting in liver copper accumulation with tissue
damage [7]. In the absence of diagnosis and treatment at this stage, the hepatic free
copper spills into the blood stream and deposits in other organs such as cornea,
brain and kidney [8].
Clinical prevalence of diagnosed WD is ~30 per million population, but this is
probably an inaccurate estimate as a recent genetic study reported the frequency of
individuals predicted to carry two mutant pathogenic ATP7B alleles to be 1/7026 [9].
The hepatic disease can remain asymptomatic for years or present as acute transient
hepatitis, fulminant hepatic failure, and either compensated or decompensated
cirrhosis. Neurological symptoms of WD include dysarthria, tremor, dystonia,
parkinsonism, oculomotor abnormalities and dysexecutive syndrome. Psychiatric
disorders are essentially depression, bipolar affection and dysthymia [8]. Brain
lesions are classically located in basal ganglia, midbrain and dentate nuclei (see
Figure 1A) but diffuse cerebral atrophy is frequent. White matter changes with
cortical lesions and abnormalities in the corpus callosum are also reported [10, 11].
Other extrahepatic features include corneal Kayser-Fleischer rings, renal
manifestations like lithiasis, osteoarticular disorders, myocardial abnormalities,
endocrine disturbances and repetitive miscarriages.
WD is biologically characterised by low serum ceruloplasmin and total copper
concentrations, associated with increased urinary copper excretion. The relative
exchangeable copper (non ceruloplasmin bound copper), measured as a ratio of total
copper, appears to be an excellent non-invasive diagnostic marker. At diagnosis,
patients with WD have a rate greater than 15% [12].
More than 500 mutations and 100 polymorphisms of the ATP7B gene are reported.
The absence of correlation phenotype/genotype, clinical heterogeneity and variable
penetrance, signify that genes modifiers may exist and influence the age of disease
onset or the phenotype.
With regards to treatment, a low copper diet is recommended and alcohol should be
avoided due to its high propensity in causing liver toxicity. Medical treatment is more
effective if administrated at an early stage of the disease and maintained for life [13].
It is typically based on copper chelators to promote copper excretion from the body
(D-penicillamine (DPA) and triethylenetetramine or Trientine) and zinc salts to
increase metallothionein synthesis and reduce copper absorption. In our experience,
DPA presents adverse effects in 30% of cases (sensitive reactions, nephrotoxicity,
hematological abnormalities, autoimmune diseases and elastopathy). Trientine has
the added inconvenience of requiring refrigerated storage and is associated with rare
sideroblastic anemia and lupus-like reactions. Adverse effects of zinc salts are
essentially gastrointestinal discomfort.
Two phases of treatment can be distinguished: the initial phase and the subsequent
maintenance therapy. During the acute phase, the major difficulty is the risk of
paradoxical worsening of neurological symptoms. A worsening of the neurological
disease is observed more frequently with DPA (13.8%) than with Trientine (8%) or
zinc salts (4.3%) [14]. In some cases, neurological deterioration is irreversible, the
disease continuing to evolve under treatment. The mechanisms of this paradoxical
worsening are discussed: treatment too slow to act in very acute forms, irreversible
tissue damage already present, direct effect of the treatment with rapid mobilization
and redistribution of copper resulting in high levels of free copper in blood and brain.
So, recommendations by experts emphasize the need of a slow increase in
chelators’ dose [8]. So far, the best therapeutic approach remains controversial, as
no prospective clinical trial has compared the different treatments. A retrospective
multicenter study analyzed the treatment outcome in 405 patients receiving DPA or
Trientine for at least 6 months [15]. After 4 years of treatment, chelation therapy lead
to hepatic improvement in more than 90% of patients and neurologic improvement in
only 62% of patients, these values did not differ between treatments. However,
neurologic deterioration was less frequently observed in patients on DPA first (6/293)
than those on Trientine first (4/38) (p=0.018). In a retrospective Polish study, 143
consecutive patients diagnosed with symptomatic WD were first line treated with
DPA or zinc salts. Neither therapy clearly appeared superior, but early worsening
was observed in 35% of patients treated with DPA and 19% of patients with zinc salts
[16]. Another retrospective study demonstrated that treatments with chelating agents
or zinc salts were effective in most patients with WD and that chelating agents are
better at preventing hepatic deterioration [17]. Despite these data do not allow a
strong recommendation, in our perspective, patients with newly diagnosed
neurological WD will still be treated in first line by chelation therapy. Choice between
DPA or Trientine depends of the treatment availability, but regardless of the
treatment improvement is not immediate and often takes 3 to 6 months.
The risk of initial neurological worsening could be lessened with tetrathiomolybdate,
another copper chelator, which acts by forming a tripartite complex with copper and
protein either in the intestinal lumen to prevent copper absorption, or in the circulation
where it blocks cellular copper trafficking [18]. However, clinical experience with this
drug remains insufficient and international studies are still only in the pipeline.
Liver transplantation should be considered in WD patients with acute liver failure or
decompensated cirrhosis as results are extremely satisfactory with 87% actuarial
patient survival rate at 5, 10 and 15 years [19]. However this remains a matter of
controversy in cases of neurological worsening without liver failure, despite reports of
70% of these patients improving after transplantation [20]. In our experience, after a
mean follow-up of five years, 12 of 16 patients (75%) improved when transplanted for
neurologic worsening. So, in this specific indication, liver transplantation must be
individually discussed.
During the maintenance phase, the major difficulty is the adherence to the treatment.
A regular clinical, biological and liver ultrasound follow-up is essential to make sure of
observance, efficiency and tolerance of the treatment, as well as to detect treatment
complications, increased liver enzymes (more frequent under zinc therapy) and liver
carcinoma. Dose adjustment during the maintenance phase is very important to
prevent overtreatment and copper deficiency. After years of regular treatment, more
often clinical signs progressively resolve and brain lesions disappear (see Figure 1A).
During pregnancy, treatments must be maintained, but dosages of drugs should be
reduced and adapted to urinary copper excretion and exchangeable copper. Since
treatment is more effective if initiated early, family screening is essential for this
autosomal recessive disorder. In relatives with presymptomatic disease, treatment is
mandatory (zinc salts or Trientine). Further treatments should focus on more site-
specific copper chelators that can act in the hepatocytes to excrete the copper-
complex into the bile. Gene therapy also seems an attractive alternative with effective
treatment on WD animal models [21, 22].
Menkes disease (MD)
MD is an X-linked recessive disorder of impaired copper absorption caused by
mutations in the ATP7A gene. Usually, developmental regression appears in boys
during the first two months of life with axial hypotonia, seizures and psychomotor
retardation. Other manifestations are relative to connective damages; coarse hair,
ligamentous hyperlaxity, skin hyperelasticity, bladder and ureter diverticula, arterial
tortuosities and anevrysms [23]. Magnetic Resonance Imaging (MRI) shows impaired
myelination, diffuse brain atrophy and tortuosity of cerebral arteries. Diagnosis of MD
can be established by detecting low levels of copper and ceruloplasmin in the serum,
and high levels in cutaneous fibroblasts. It is confirmed by identification of the gene
mutation. For some patients, parenteral administration of Histidine-copper improves
the neurological outcome and increases lifespan, but the prognosis remains
inevitably poor. Death usually occurs by 3 years of age, but some patients can
survive beyond 10 years. In 5-10 % of the patients, a milder form of MD presents with
a later onset, more moderate symptoms and longer survival. Preliminary results of
brain-directed ATP7A gene therapy using recombinant adeno-associated virus in a
mouse model of MD appear highly promising [24].
Other copper disorders
Occipital horn syndrome and ATP7A-related distal motor neuropathy are also
associated with ATP7A mutations. MEDNIK (mental retardation, enteropathy,
deafness, peripheral neuropathy, ichthyosis, and keratoderma) syndrome and
Huppke-Brendl syndrome are newly recognised genetic disorders that may indirectly
affect the function of ATP7A [23, 25]. MEDNIK syndrome is caused by mutations in
the s1A subunit of adaptor protein complex 1 (AP-1), which leads to detrimental
effects on ATP7A trafficking [26]. Huppke–Brendel syndrome is caused by mutations
in an acetyl-CoA transporter, SLC33A1, needed for acetylation of one or more
copper proteins [27]. Clinical, biochemical, molecular features and treatment options
of these rare diseases are summarized in Table 2.
3. Acquired disorders: copper deficiency and copper excess/toxicosis
Acquired Copper deficiency (ACD)
In developed countries, ACD is rarely due to a low dietary intake of copper
(malnutrition or prolonged parenteral nutrition without copper supplementation).
Instead, the two main causes responsible for inadequate supply of copper are
digestive disorders with impaired absorption and/or consumption of high dose of zinc
that provokes a zinc-induced copper deficiency. Digestive conditions can originate
from various malabsorption syndromes including celiac disease, inflammatory bowel
disease, upper gastro-intestinal surgeries and bariatric surgery to combat obesity.
High intake of zinc is usually associated with chronic use of dental adhesives
enriched in zinc [8] but prolonged zinc treatment in WD can also cause ACD in
extreme cases [28]. The precise molecular mechanisms of ACD are unknown [29].
Manifestations of ACD start with hematologic then neurologic abnormalities. Anaemia
and neutropenia are the most common hematologic findings but pancytopenia can be
also present [30]. Neurologic symptoms can be initially limited to ascending
paresthesias and gait disorder but can also mimic a B12 deficiency phenotype with a
posterior cord syndrome or a subacute combined degeneration. On most occasions
spinal cord MRI classically shows a posterior high T2 signal in cervical or dorsal
level, but it may also be normal. B12 dosage and CSF are always normal. Low serum
copper and ceruloplasmin levels confirmed the diagnosis but can be differentiated
from WD through urinary copper levels being typically low or normal. Treatment is
based on a chronic copper supplementation (but doses and duration are not well
established) and is dependent on the management of underlying risk factors. In our
experience, copper should be started as rapidly as possible with subcutaneous or
parenteral high doses (minimum 4 mg/d) and then maintained over years with oral
intake of a minimum of 2 mg/d copper. Using this regime, disturbances in copper and
hematology are rapidly resolved in a few weeks, MRI normalizes in a year but
neurologic improvement takes much longer if benefits are seen at all.
Acquired copper toxicity
Acute copper toxicity tends to results from accidental copper contamination of
drinking water or other beverages stored within copper-containing vessels. Clinical
manifestations range from a metallic taste, nausea, vomiting and diarrhoea, through
to jaundice, hemoglobinuria, hematuria, anuria, and oliguria. A lethal dose is ~1000
times the normal dietary intake. Chronic copper poisoning arises from accumulation
within the liver but is exceptional due to highly efficient systemic control mechanisms
for copper homeostatic that can alter intestinal absorption and biliary excretion in
response to the body’s copper levels [31].
Iron and Central Nervous System
1. Iron metabolism, brain pathology and iron chelation
Iron has allowed the existence of life on earth through an ability to act as an electron
donor for photosynthesis and aerobic respiration via mitochondrial oxidative
phosphorylation. Iron homeostasis relies on the orchestration of a network of
systemic and cellular mechanisms for the acquisition, internal distribution and
employment of iron [32-34]. Disruption of links in the metabolic network can lead to
mislocalization of iron in specific cellular compartments or tissues (causing localized
siderosis and thus damage) and impaired redistribution of iron, generating a
“deficiency in the midst of abundance” [35-37].
Damage arising from siderosis is mostly from the potent pro-oxidant and redox-
cycling capacity of iron, making it a key player in upstream mechanisms that
precipitate cell death. Iron’s catalysis of reactive oxygen species (ROS) formation
from by-products of oxygen consumption affects neuronal functions either by directly
damaging cell components, through the Fenton reaction, or by chemically affecting
signal mediators [38-40].
The recent resumption of interest for iron in the brain pathologies can be explained
by several facts. First, iron maldistribution with iron accumulation (i.e. regional
siderosis) have been clarified with greater resolution, using a variety of imaging
techniques, as an early feature in pathologically affected brain regions from
Neurodegeneration with Brain Iron Accumulation (NBIA), Friedreich ataxia (FA),
Parkinson’s disease (PD), Alzheimer’s disease (AD) and Amyotrophic Lateral
Sclerosis (ALS). Second, accumulative data demonstrate a pivotal role of iron in the
physiopathology of cell death as exemplified by; the defective synthesis of the cluster
iron sulfer in FA, the exacerbation of dopamine oxidation in PD, and the involvement
of the canonical proteins of AD in iron metabolism (i.e. E-Amyloid precursor protein,
Tau, ApoE, presenilin). Finally, therapeutic perspectives with the new concept of
conservative iron chelation have shown promising outcomes in preclinical and clinical
testing.
Despite these promising advances, the exact contribution of brain siderosis on
aetiology of these diseases remains to be fully elucidated. Moreover, while iron
accumulation with neurodegeneration has been a major focus of previous research it
is increasingly evident that iron deficits caused by maldistribution are just as
deleterious to behavioural outcome and increasingly understood to be a major
contributor to cognitive impairment in our society (e.g. the association with juvenile
obesity and iron deficiency [41]). In all these disorders, the simultaneous dearth and
surplus of regional iron within the brain pose new challenges in drug therapy, with the
need to detoxify discrete siderotic foci without affecting essential iron-dependent
functions and conversely, replenish iron-deprived regions without overloading those
already in surplus. The traditional role of iron chelation therapy has been to reduce
body iron burden of excess metal and its safe excretion in a complexed form.
However, we and others have introduced a more conservative mode of iron chelation
with a dual activity based on scavenging labile metal not considered to be
functionally required and redeploying it to cell acceptors or the physiological iron
transporter transferrin family. This “scavenging and redeployment” is a proposed
mode of action for the prototype drug deferiprone and has been found to correct
aberrant iron distribution and minimizing / prevent systemic loss of chelated metal in
a range of animal models and humans [42, 43].
2. Monogenetic Orphan diseases; Neurodegeneration with brain iron
accumulation (NBIA)
NBIA is a heterogeneous group of disorders with a prevalence of ~0.5 / 100,000 but
a highly variable age of onset, partly depending on the causative genetic abnormality.
This syndrome is clinically characterized by the variable combination of i) movement
disorders (dystonia/parkinsonism/chorea) that usually are the main manifestation of
the disease and predominate in the oro-facial and bulbar muscles, ii) pyramidal
syndrome, iii) cognitive deterioration and iv) psychiatric disturbances. Brain MRI
shows bipallidal hyperintensity on T2 and T2* (more sensitive) weighted sequences
that reflect the alteration of iron homeostasis in these areas (See Figure 1B). Other
clinical or neuroimaging abnormalities can be seen depending on the cause (see
Table 3). It is important for clinical practice to keep in mind that a time lag can be
observed between clinical manifestations and neuroimaging abnormalities; some
symptomatic patients still have a normal MRI at initial stages and conversely some
patients are asymptomatic despite bipallidal hyperintensity.
NBIA can be divided into two groups, primary disorders of iron metabolism
(neuroferritinopathy and aceruloplasminemia) and disorders in which alteration of
iron homeostasis is secondary to neuronal stress induce from another origin
(Panthotenate Kinase Associated Neurodegeneration (PKAN), PhosphoLipase A2
Group VI Associated Neurodegeneration (PLAN), Fatty Acid 2 Hydroxylase
associated Neurodegeneration (FAHN), Mitochondrial membrane Protein Associated
Neurodegeneration (MPAN), Beta-propeller Protein Associated Neurodegeneration
(BPAN), and Coenzyme A synthase Protein Associated Neurodegeneration (CoPAN)
[44]. Diagnosis is confirmed by molecular analysis of the various culprit genes.
Aceruloplasminemia leads to a dramatic reduction of the ferroxidase activity in
ceruloplasmin that prevents astrocytic iron export and the safe incorporation of iron
into extracellular transferrin. In the absence of functional ceruloplasmin, astrocytic
iron accumulation leads to neurons suffering from iron deprivation in the early stages
of the disease, and eventually promotes iron-mediated oxidation. Neuroferritinopathy
results from an alteration of iron storage by ferritin polymers with subsequent release
of free iron and iron-mediated oxidation. Interestingly, secondary alterations of iron
homeostasis are mostly linked to disorders of synthesis and the remodelling of
complex lipids. Basically, treatment is symptomatic and currently there are no
registered treatments for preventing the gradual pathological deterioration over
decades (see Figure 1B). However, the benefit of iron chelator and particularly
deferiprone has been proposed through open label trials in PKAN [45-48] despite
efficacy remaining to be determined in on going randomized clinical trials.
3. Polygenic Neurodegenerative disorders
Parkinson’s Disease (PD)
PD arises from a progressive degeneration throughout the nigrostriatal tract, most
marked in the Substantia Nigra pars compacta (SNc). Depletion of striatal dopamine,
resulting primarily from loss of SNc neurons, results in characteristic symptoms of
disrupted motor coordination and cognitive impairment in the latter stages. Similar to
NBIA, PD is characterised by iron accumulation in the basal ganglia with elevation
above normal ageing greatest in the SNc [49-55] of patients and animal models [40,
56]. Indeed, since its first anatomopathological description in 1924 [57], iron
accumulation has now become a cardinal feature of regional cellular degeneration,
as demonstrated with MRI [52, 54, 55] and ultrasound [58]. Several reasons can
explain the vulnerability of the SNc to ROS and dysregulation of a pro-oxidant such
as iron would clearly exacerbate ROS induced toxicity. Metabolism of dopamine,
through pathways in which several are iron-dependent, expose dopaminergic
neurons to high ROS productivity. When these dopamine metabolites are produced
within vesicles they are comparatively protected against oxidation, but when formed
within the cytoplasm become toxic. D-Synuclein (D-syn), a pathological protein
associated with PD, may be implicated in this altered dopamine metabolite location
as a reported role of D-syn is in the formation of vesicles and PD induced changes to
the structure of D-syn can lead to disrupted vesicle formation. Changes in
neurotoxicity within the cytoplasm may be compounded by D-syn aggregating in PD
to form Lewy bodies, another hallmark of PD, which also combines with lipids, redox-
active iron and dopamine metabolites to form a site for redox cycling. The
aggregation of D-syn in the presence of iron also has a positive feedback loop
whereby together they induce a defective sequestration of dopamine into vesicles,
further enhancing the oxidative metabolism of dopamine into harmful dopamine
quinones [59]. Lastly, autonomous pacemaking within the SNc is substantially higher
than other dopaminergic regions (e.g. ventral tegmental area and SN pars reticulate),
thus creating a higher level of ROS and increasing vulnerability of this region to
oxidative stress [38].
The presence of elevated labile iron in the SNc of PD patients, in particular within the
mitochondrial subcellular compartment, has been proposed to result from one or
more of the following factors [60]; increased iron influx facilitated through transferrin
receptor-2/divalent metaltransporter-1 endocytosis or the diffusion of ferric citrate
[61]; loss of intracellular homeostatic regulation involving iron, dopamine and
neuromelanin [62]; impaired iron efflux [63-65].
Given the deleterious effects of elevated iron in the SNc of PD patients, a therapeutic
strategy that reduces the levels of labile iron is likely to be neuroprotective. Chelation
as a viable therapeutic strategy requires targeting to all forms of regional siderosis,
but with the prerequisite of sparing systemic metal depletion [35, 66]. We and others
selected deferiprone (DFP) as a paradigm in the suitability of membrane permeable
chelation to confer neuroprotection through conservative iron chelation. Indeed, we
demonstrated both with PD models and patients that DFP rescued iron-overloaded
dopaminergic neurons by scavenging labile iron, especially from mitochondria, and
diminished labile iron-mediated oxidative damage so as to be neuroprotective in
animal models and improve symptoms in patients. Moreover, DFP had the capacity
to deliver chelated metal to endogenous apo-transferrin (iron unbound transferrin)
within extracellular fluid [35], and cause no systemic loss of iron even after 2 years of
treatment [43]. These promising results have provided the opportunity to now assess
this therapeutic paradigm in a larger population through a European randomised
clinical trial (www.fairpark2.eu).
Alzheimer’s Disease (AD)
Iron elevation in affected areas of AD has been well-characterised in living patients
using MRI, and in post mortem brains using multiple techniques [40]. While early
studies with high field T2-weighted MRI suggested amyloid plaques containing iron
[67], more recent developments using 7-T MRI have demonstrated iron deposition
also within activated microglia surrounding the plaque [68, 69]. Hippocampal iron
accumulation also localizes to neurofibrillary tangle-containing neurons and the
neuritic processes surrounding senile plaques in AD [70]. Genetic and biochemical
markers have identified a concerted systemic iron homeostatic dysregulation in
patients with AD [71] and colleagues have calculated the impact of iron on
longitudinal AD outcomes [72]. Using ferritin (the major iron binding protein) in CSF
as an index, high brain iron load was found to associate with poorer cognition and
brain atrophy over a 6-year period. The magnitude of CSF ferritin on these and other
AD outcomes is comparable to the Tau/AE42 ratio typically considered as the best
diagnostic CSF biomarker for AD. CSF ferritin levels also formed a remarkable
association with CSF ApoE levels and subjects with APOEH4 isoform have elevated
CSF ferritin compared to patients without this AD risk allele [72]. Intriguingly, iron
appears to regulate ApoE expression and secretion from brain derived cells [73].
Lastly, interactions between variants in the transferrin gene (TF) and the
hemochromatosis gene (HFE) also have been identified and replicated in multiple
cohorts for association with sporadic AD [74].
A number of additional pathologically relevant proteins associated with AD have also
been implicated with regulating cellular iron homeostasis whereby disruption in the
expression or location of these proteins exacerbates oxidative stress induced
neurotoxicity. Of particular focus has been the regulatory pathway required to
facilitate the cellular efflux of iron. Control of APP expression by iron regulatory
protein supports an interaction with iron status [75] and biological evidence has
illustrated a role of APP in neuronal iron efflux through interaction with the iron pore
ferroportin [76]. Prior to this discovery no mechanism was known for endogenous
regulation of neuronal iron export and latter studies have confirmed the requirement
of APP on the cell surface to stabilize ferroportin in its functional location [77 , 78 ,
79 , 80]. Alterations in the correct processing of APP, as with the AD-associated
familial mutation [81], or when APP trafficking to the cell surface is altered [65] leads
to neuronal iron accumulation. Subsequent studies have implicated tau in the
intracellular trafficking of APP to the cell surface, and accordingly a deficiency in this
role of tau leads to reduced APP and ferroportin on the cell surface, intraneuronal
iron accumulation and a subsequent increased sensitivity to oxidative stress [65].
Metal chelation therapy is a proposed target for AD but this has principally focused
on compounds with a greater affinity for copper and zinc. Preclinical evidence has
however indicated that iron selective chelation is neuroprotective in AD models by
reducing features of pathology and behavior associated with AD [82]. It has recently
been proposed that iron accumulation and other hallmarks of the disease in these
models may be alleviated by restoring or substituting the iron regulatory role of the
pathological proteins associated with the disease (e.g. APP and tau) [63].
Amyotrophic lateral sclerosis (ALS)
Many lines of evidence indicate that there is an iron dyshomeostasis in ALS. Indeed,
iron serves as an important cofactor for a number of enzymes involved in pivotal
biological activities altered in ALS, and the high redox active nature of iron means
that it may be a major generator of the free radicals prevalent with the disease.
Serum ferritin levels are higher in ALS patients versus healthy and disease controls
[83] and this elevation correlates with a shorter survival time in these patients [84-86].
While total iron levels remain unchanged, altered transferrin saturation in ALS
patients supports an altered iron loading [85]. Cerebrospinal fluid of ALS patients
also indicates a two-fold increase in levels of inappropriate iron ligands, representing
the proportional increase in iron redox activity and hydroxyl radical production
compared to controls [87]. Routine MRI studies have also shown hypo-intense
signalling in the motor cortex on T2-weighted images in some ALS patients [87-89].
Pathological studies using a histological stain for iron and immunostaining for ferritin
confirm this signal to originate from increased iron accumulation in cells resembling
microglia from the middle and deep layers of the motor cortex [89].
Irregularities in iron homeostatic pathways have also been observed in mouse
models of ALS that carry familial mutations in SOD1 (superoxide dismutase 1). Both
the G37R and G93A mutant models have caudal-to-rostral gradient in the spinal cord
of iron-related changes at end stage of the disease (i.e. 12 months of age), however
in the case of SOD1 (G93A) this distribution showed a reverse pattern at a younger
age [90]. The iron responsive protein changes in the cervical region parallel clinical
disease evolution. Since mitochondrial disruption is thought to play a major role in
ALS, it is worth noting that mitochondrial ferritin (a protein known to trap iron in the
mitochondria) is also markedly increased in SOD1 (G37R) mice and could implicate
the disease associated iron accumulation with neuodegeneration similar to FA [90].
Iron chelation therapy in rodent models of familial ALS are able to increase the mean
life span, spinal motor neuron survival and locomotor function in the SOD1 (G37R)
along with the decrease in iron accumulation when the lipophilic iron chelator SIH
(salicylaldehyde isonicotinoyl hydrazine) is administered [90]. More recently, VK-28
and M30 have also provided delayed onset of ALS symptoms, lifespan extension and
reduced spinal cord motor neuron loss in the SOD1 (G93A) model [91]. We can
confirm that an increase in R2* signal is present within the spinal cord, brainstem and
motor cortex of early ALS patients, which is partially corrected by deferiprone at 30
mg/kg/day (publication in preparation). While it is less clear whether iron has a
pathological involvement with other ALS-associated proteins such as TDP-43 [92],
the sporadic patient and familial ALS SOD1 model data provides a strong case for
assessing this therapeutic paradigm in a large population similar to the recent
Fairpark randomised clinical trial carried out on PD patients.
Manganese and Central Nervous System
After its absorption by inhalation or through the gastrointestinal tract, manganese
(Mn) predominantly accumulates in the liver and the brain (especially in the basal
ganglia, SN and the cortex). As with copper, the hepatobiliary system has a major
role in the manganese homeostasis. In the gut, dyshomeostasis of other metals may
have an effect on Mn absorption as an iron deficiency increases uptake. As with iron
and copper, excessive accumulation of this essential nutrient yields toxicity. This may
arise through rare mutation such as within the SLC30A10 gene (syndrome of liver
cirrhosis, polycythemia, dystonia and hypermanganesemia) or more often due to
excessive exogenous exposure that leads to manganism. Manganism has been
described in occupationally exposed workers or drug users of homemade
ephedron/methcathinone. Patients may be asymptomatic for months or years after
exposure, but progressively develop slow movements, irritability, aggressiveness,
and hallucinations. By later stage, features include extrapyramidal syndrome that is
unresponsive to L-dopa, tremor, balance disturbances with a dystonic cock-walk gait
and postural instability, facial muscle spasms and cognitive impairment [93, 94].
During the exposure period, and before phenotypic changes, blood and urine Mn
levels are high and brain MRI displays a symmetrical high T1 signal in the basal
ganglia (mostly in the GP). To date there are no effective treatments for manganism
as chelators only decrease Mn levels but don’t improve the symptoms, thus
indicating that deterioration may still occur even after Mn exposure has stopped.
Chronic liver failure may be another cause of cerebral Mn accumulation as the
hepatobiliary system fails to keep metal homeostasis. In this acquired hepatocerebral
degeneration, patients may present with parkinsonism, ataxia, tremor and cognitive
impairment without signs of toxic-metabolic hepatic encephalopathy and have an
abnormal brain MRI with bipallidal T1 hyperintensity. Neuropathologic examination
showed that pallidal manganese concentrations are sevenfold higher that controls
and fourfold higher that patients suffering from chronic liver failure but with a normal
brain MRI [95]. No clinical data exist of the efficacy of lowering Mn by diet or
chelating therapy in chronic liver failure but Trientine administration and liver a
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Figure Legends
Figure 1 Examples of brain MRI evolution over three years of chelating treatment
metal associated neurological diseases. A. Wilson’s disease: bilateral hypersignal in
Flair sequences of nuclei dentate (i.) and striatum (ii.). Normalization of brain MRI
after three years of chelation by D-Penicillamine (DPA). B. Neuroferritinopathy:
hyper- and hypo-signal in striatum in Flair sequences (i.) and T2* (ii.) sequences.
Slight worsening of the abnormal signals is observed despite three years of chelation
by deferiprone (DFP).
2013
2016
2016
B. Neuroferri nopathy
A. Wilsons disease
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Table 1 Main characteristics and treatment of poisoning by non-essential heavy metals
Heavy
metal
Mode of
intoxication
Major sites of
accumulation
General
presentation
Neurologic
presentation
Diagnosis tests Treatment
Aluminum
(Al)
[96, 97]
Occupational
exposure
(inhalation of
fumes)
Hemodialysis
IV boiled methadone
CNS
Bones
Liver
Kidneys
Bone pain
Osteomalacia
Aplastic bone
disease
Anaemia
Encephalopathy
Seizures
Myoclonus
Tremor
Ataxia
Personality changes
Blood Aluminum
level
Reduce or remove the
source of exposure
Chelation by
Deferoxamine
/Desferrioxamine,
deferasirox
Cadmium
(Cd)
[97, 98]
Chronic Inhalation of
fumes or dust
(silver jewellery
industry)
CNS
PNS
Kidneys
Bones
Renal tubular
damage
Osteomalacia
Neuropsychiatric
manifestations
Polyneuropathy
24-hour urinary
Cadmium test
Reduce or remove the
source of exposure.
Discuss chelation by
Oral DMSA and/or iv
DTPA
Lead
(Pb)
[97, 99]
Occupational
exposure
(inhalation)
Diet/ ingestion
CNS
PNS
Liver
Kidneys
Bone marrow
Bone
Digestive signs
(abdominal
pain, nausea,
constipation)
Nephropathy
Anaemia
Headaches
Sleep disturbances
Attention deficit
Memory disturbances
Neuropathy
Blood Lead level Reduce or remove the
source of exposure
Discuss chelation by
DMSA
Mercury
(Hg)
[97, 100]
Dental amalgam.
Fish consumption
(tuna, shark,
swordfish)
Gastrointestinal
tract
CNS
PNS
Kidneys
Gingivitis
Stomatitis
Hypersalivation
Metallic taste
Nephropathy
Fatigue
Neuropathy
Irritability
Tremor
Sleep disturbances
Memory and
concentration deficit
Blood and urine
Mercury levels
Reduce or remove the
source of exposure
Discuss chelation by
DMPS
CNS: Central Nervous System; PNS: Peripheral nervous system; DMSA : dimercaptosuccinic acid ; DTPA : Diethylenetriaminepentaacetic
acid ; DMPS : dimercaptopropane sulfonate
Table 2: Clinical, biochemical, molecular features and treatment options in very rare copper transport disorders.
Disease Genetic
transmission
Molecular
defects
Age at
diagnosis
Neurological
features
Other features Biochemical
findings
Treatment
options
Prognosis
Occipital
horn
syndrome
(Elher Danlos
syndrome
type 9)
X-linked
recessive
ATP7A
gene
Childhood Absent or mild
dysautonomia
Muscle weakness
Occipital exostose,
Bladder diverticula,
Inguinal hernias,
Skin laxity,
Hyperelasticity
Serum copper &
ceruloplasmin
normal or low
Copper
replacement
discussed
Long-term
natural
history not
known
ATP7A-
related
distal motor
neuropathy
X-linked
recessive
ATP7A
gene
Adult Atrophy and
weakness of distal
muscles in hands
and feet,
Foot deformities
- Serum copper &
ceruloplasmin
normal
Copper
replacement
discussed
Long-term
natural
history not
known
MEDNIK
syndrome
Autosomal
recessive
AP1S1
gene
First year
of live
Mental retardation
Deafness
Neuropathy
Enteropathy
Ichthyosis
Keratodermia
Serum copper &
ceruloplasmin
low
Hepatic copper
accumulation
Zinc therapy Poor
Huppke-
Brendl
syndrome
Autosomal
recessive
SLC33A1
gene
First year
of live
Developmental delay,
Cerebellar
hypoplasia,
Hearing loss,
Cerebellar hypoplasia
and hypomyelination
in brain MRI
Congenital
cataracts
Serum copper &
ceruloplasmin
low
None
available at
present
Poor
Table 3: Clinical, biochemical, molecular features and treatment options in very rare Neurodegeneration with Brain Iron
Accumulation (NBIA) disorders.
Disease Genetic
transmission
Frequency Age at
diagnosis
Neurological
features
MRI
characteristics
Neuropathological
findings
Treatment options
Pantothenate kinase-
associated
neurodegeneration
(PKAN) (NBIA1)
PANK2 +++ Juvenile to
young
adulthood
Dystonia
Spasticity
Parkinsonism
Retinopathy
Hypo- with central
hyper-intensity
of the GP –
‘Eye of the
Tiger’
Neuronal loss in GP
Reduced myelin
Normal SN
Widespread gliosis in GP
Baclofen (dystonia)
Anti-cholinergic
Anti-convulsives
(seizures)
Benzodiazepines
(muscle-relaxation)
Iron chelation discussed
PLA2G6-associated
neurodegeneration
(PLAN) (NBIA2)
PLA2G6 ++ Juvenile to
young
adulthood
Hypotonia
Spasticity
Dystonia
Parkinsonism
Optical atrophy
Hypo-intensity of
the GP
Cerebellar
atrophy
Cerebellar, Cortical, GP
and Brainstem atrophy
Levodopa/carbidopa
(parkinsonism)
Baclofen (dystonia)
Anti-convulsives
(seizures)
Benzodiazepines
(muscle-relaxation)
Iron chelation discussed
Neuroferritinopathy
(NBIA3)
FTL + Adult Dystonia
Spasticity
Parkinsonism
Hypo- and –
hyper-intensity
of basal
ganglia, in
particular the
GP and SN
Atrophy mostly in
Putamen and
Cerebellum but also SN
Some gliosis
Same as PLAN
Mitochondrial
membrane-associated
neurodegeneration
(MPAN) (NBIA4)
C19orf12 ++ Juvenile to
young
adulthood
Dystonia
Spasticity
Parkinsonism
Optical atrophy
Hypo- and hyper-
intensity of the
GP
Hypo- intensity of
the SN.
Streaking of MML
Neuronal loss in GP
Reduced myelin
SN and GP atrophy
Widespread gliosis
Same as PLAN
COASY protein-
associated
neurodegeneration
(CoPAN)
COASY + Childhood Dystonia
Spasticity
Dysarthria
Parkinsonism
Optical atrophy
Hypo- with central
hyper-intensity
of the GP
Neuronal loss in GP
Reduced myelin
Widespread GP gliosis
(Similar to PKAN)
Same as PLAN
FA2H-associated
neurodegeneration
(FAHN)
FA2H + Juvenile to
young
adulthood
Dystonia
Ataxia
Spasticity
Hypo-intensity of
the GP
Cerebellar and
cortical atrophy
White matter lesions and
demyelination
Brainstem atrophy
Same as PLAN
Aceruloplasminaemia CP + Adult Dystonia
Dyskinesia
Cerebellar ataxia
Cognitive
impairment
Hyper-intensity of
striatum,
thalamus and
dentate
Severe neuronal atrophy
in Putamen and Dentate
Nucleus.
Atrophy in GP, SN, Cortex
& Cerebellum (Purkinje)
Widespread gliosis
Same as PLAN
CP supplementation
discussed
E-propeller-associated
neurodegeneration
(BPAN)
WDR45 ++ Childhood Parkinsonism
Dystonia
Cognitive
impairment
Hypo-intensity of
the GP/SN with
central hyper-
intense line
Cerebral and
Cerebellar
atrophy
Neuronal loss in SN & GP
Cerebellar atrophy in
Purkinje and granular
layers
Cortical atrophy
Gliosis in Putamen and
Thalamus
Same as PLAN
GP: globus pallidus; SN: Substantia nigra; MML: Medial medullary lamina
